Biogen’s Post

🅾 3 HEALTH PRODUCT RED FLAGS Top 3 healthcare products red flags that can save you money if you know what not to buy... 1️⃣ Claims to treat many diseases at a time A product claims to treat many diseases like diabetes, cancer, autoimmune, and heart diseases all at the same time that sounds to be true but probably is a placebo. 2️⃣ Testimonials and Stories If the main evidence to support the product comes from the testimonials and stories from their customers. 3️⃣ Missing Clinical claims Use of vague scientific terms without any clinical data to back up their claims. P.S. Would you like to add any? #medicalwriting #pharma #clinical #healthcare #healthcarebusinesses #healthcareproducts #redflag #healthcareprofessionals

Digital Therapeutics (DTx) will redefine Chronic Disease Management. Under our "Leadership Series" Health Parliament is releasing the report 'The Promise & The Potential of Digital Therapeutics (DTx) for Digital Chronic Disease Management (DCDM)- A New Therapeutic Field'. We are also renaming the field of Chronic Disease Management (CDM) to Digital Chronic Disease Management (DCDM). The report explores how the integration of Digital Therapeutics into mainstream healthcare will expand the scope of treatable conditions and usher in a more patient-centric and precision-oriented era of medicine. To read more, download: https://lnkd.in/d4ShfHqr #health #healthcare #digitalhealth #publicpolicy #publichealth #digitaltherapeutics #chronicdisease #diseasemanagement

Defining and achieving remission in Crohn's disease: watch the interview with Prof. Edouard Louis, MD, PhD, on Medfyle. Click to watch: https://lnkd.in/dyFcFsDc #IBD #Medicine #Therapy #GETTECU #Trials

By using #BiosimilarMedicines, healthcare professionals have access to a wider spectrum of treatment options and opportunities to change patient treatment pathways for the better. Take, for example, biosimilars Infliximab and Adalimumab, used for treating rheumatoid arthritis. Prior to biosimilars becoming available, patients had to meet a higher threshold (i.e. have a more severe condition) and waited longer to access treatment. Now biosimilars have made this medication available to those with moderate rheumatoid arthritis too, starting them earlier on a valuable treatment pathway. Discover more by following #GlobalBiosimilarsWeek! https://lnkd.in/dDDCRmN8 #biosimilars #rheumatoidarthritis #NHS

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD

❗There is a pressing need for innovative pharmacological therapies to treat focal segmental glomerulosclerosis (FSGS), a rapidly progressing disease that frequently leads to end-stage renal disease, necessitating dialysis or a kidney transplant. 🧭Find out what the future holds for #FSGS and if your asset is positioned to make the greatest difference for these #patients.   Subscribed clients have the ability to: ✅Submit proprietary questions with insights that are exclusive to you ✅Partner with Spherix Global Insights market experts on key business questions, customized presentations and advisory services ✅Request ad-hoc data cuts and analyses 🌍Explore Spherix's FSGS services on our Client Portal. #focalsegmentalglomerulosclerosis

It's almost Rare Disease Day (Feb 29th)! ZoomRx surveyed 100 MDs treating complex rare diseases to understand challenges and needs.   Here's what we found: ➡️Only 17% of MDs feel very confident in managing and diagnosing rare diseases. ➡️Developing treatment plans and early diagnosis are major hurdles, highlighting the need for enhanced training, resources, and diagnostic tools. ➡️Gene-targeted therapies are seen as the most promising therapeutic approach by over 60% of MDs, reflecting a shift towards personalized medicine. Check for more details: https://bit.ly/49S00tm   Stay tuned for more insights from our survey! Upcoming posts will explore unmet needs, patient challenges, and the role of pharma manufacturers.   #rarediseaseday #rarediseaseawareness #rarediseases #rarediseaseday2024 #rarediseasemonth #rarediseaseresearch #healthcare

The American Diabetes Association returns for its 84th Annual Scientific Session on June 21st, bringing together researchers, healthcare professionals, and industry experts to delve into the latest advancements in diabetes research, treatment, and care.    With session themes focusing on therapeutics, management of acute or chronic complications, and behavioural medicine, it’s worth highlighting that the effectiveness of any treatment depends on its efficacy, safety, and patient adherence. Patient-centric integrated care approaches that enable real-time patient monitoring play a pivotal role in ensuring medication adherence and mitigating the risk and severity of complications associated with obesity, such as diabetes and hypertension.   Get in touch to arrange a meeting with Hakim Yadi Ph.D. OBE! Learn more about how Closed Loop Medicine is facilitating personalized disease management through our expanding portfolio of drug-plus-software combination products, to improve the effectiveness of medicines, such as GLP-1s, while reducing the impact of adverse effects:  https://shorturl.at/fMcea   #ADA2024 #TechBio #PrecisionCare

You or someone you love could be part of developing new therapies for congenital hyperinsulinism. ⁠ ⁠ The ACHIEVE clinical trial is seeking children and adults with congenital hyperinsulinism for participation. The study is evaluating a long-acting investigational drug that acts like glucagon in the body to maintain blood sugar levels. Dosing is only required once per week. During the study qualified participants will be provided with a continuous glucose monitoring system, glucometer, and patient diary. ⁠ ⁠ Visit http://ACHIEVE.study for more information. ⁠ #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

Drug Repurposing with the help of AI: Opportunities: Accelerated time to market, cost savings. Risks: Lack of validation, limited applicability. What do you think?